Profound Medical Corp.

Toronto Stock Exchange PRN.TO

Profound Medical Corp. Gross Profit Margin for the year ending December 31, 2023: 60.87%

Profound Medical Corp. Gross Profit Margin is 60.87% for the year ending December 31, 2023, a 34.61% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Profound Medical Corp. Gross Profit Margin for the year ending December 31, 2022 was 45.22%, a 5.28% change year over year.
  • Profound Medical Corp. Gross Profit Margin for the year ending December 31, 2021 was 42.95%, a -9.70% change year over year.
  • Profound Medical Corp. Gross Profit Margin for the year ending December 31, 2020 was 47.56%, a -16.95% change year over year.
  • Profound Medical Corp. Gross Profit Margin for the year ending December 31, 2019 was 57.27%, a 80.92% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
Toronto Stock Exchange: PRN.TO

Profound Medical Corp.

CEO Dr. Arun Swarup Menawat MBA, Ph.D.
IPO Date July 10, 2018
Location Canada
Headquarters 2400 Skymark Avenue
Employees 131
Sector Health Care
Industries
Description

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Similar companies

MDNA.TO

Medicenna Therapeutics Corp.

USD 0.91

-2.78%

HLS.TO

HLS Therapeutics Inc.

USD 2.70

2.33%

StockViz Staff

January 15, 2025

Any question? Send us an email